The adapted supply and commercialization conditions to better achieve the development of the first oral formulation of arsenic trioxide for the treatment of cGvHD should provide the best chances for final market access.
July 2, 2024, 7.00am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announce the signature of global licensing, supply and commer